Shots:

• On Feb 05- 2020- GlycoMimetics received notice for termination of its license agreement signed on Oct 07- 2011 from Pfizer due to failure of its P-III RESET study to achieve 1EPs & 2EPs in patients with SCD experiencing VOC aged ≥6yrs.
• On termination- Pfizer will lose rights to develop & commercialize licensed therapies including rivipansel and will grant a non-exclusive license to GlycoMimetics to utilize Pfizer’s IP- developed in connection with licensed therapies
• Glycomimetic will not incur any termination penalties as a result of the termination of the license agreement. Rivipansel is an investigational therapy for VOC in people with SCD- act by inhibiting selectin interactions and reduces the enhanced cell adhesion that resulted in VOC

Click here ­to­ read full press release/ article | Ref: Sec filing | Image: Pfizer